The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders ; volume:36 ; number:5 ; day:22 ; month:3 ; year:2022 ; pages:451-482 ; date:5.2022
CNS drugs ; 36, Heft 5 (22.3.2022), 451-482, 5.2022
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-022-00907-3
- URN
-
urn:nbn:de:101:1-2022071706321628848692
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bradlow, Richard C. J.
- Berk, Michael
- Kalivas, Peter W.
- Back, Sudie E.
- Kanaan, Richard A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: The Potential of N‑Acetyl‑L‑Cysteine (NAC) in the Treatment of Psychiatric Disorders
The DSM-5: Hyperbole, Hope or Hypothesis?
Pathways to new drug discovery in neuropsychiatry
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?
Moving towards a population health approach to the primary prevention of common mental disorders
Tobacco smoking predicts depression and poorer quality of life in heart disease
Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
Food policies for physical and mental health
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
Using lithium as a neuroprotective agent in patients with cancer
Correction to: The Potential of N‑Acetyl‑L‑Cysteine (NAC) in the Treatment of Psychiatric Disorders
The DSM-5: Hyperbole, Hope or Hypothesis?
Pathways to new drug discovery in neuropsychiatry
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?
Moving towards a population health approach to the primary prevention of common mental disorders
Tobacco smoking predicts depression and poorer quality of life in heart disease
Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
Food policies for physical and mental health
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
Using lithium as a neuroprotective agent in patients with cancer
Correction to: The Potential of N‑Acetyl‑L‑Cysteine (NAC) in the Treatment of Psychiatric Disorders
The DSM-5: Hyperbole, Hope or Hypothesis?
Pathways to new drug discovery in neuropsychiatry
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?
Moving towards a population health approach to the primary prevention of common mental disorders
Tobacco smoking predicts depression and poorer quality of life in heart disease
Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
Food policies for physical and mental health
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?